Caplacizumab 10mg powder and solvent for solution for injection vials
NHS hospitals in England used £18,564,783 of indicative cost of Caplacizumab 10mg powder and solvent for solution for injection vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 25.7% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Caplacizumab 10mg powder and solvent for solution for injection vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Caplacizumab 10mg powder and solvent for solution for injection vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| University College London Foundation Tr | £5,713,197 |
| Univ Hpl B/Ham Nhs Foundation Trust | £2,067,357 |
| Sheffield Teaching Hospitals Nhs Trust | £1,967,925 |
| Aintree University Hospital Nhs Ft | £1,955,496 |
| Univ Hpls Bristol Nhs Foundation Trust | £1,897,494 |
| Nottingham University Hospitals Trust | £1,441,764 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,077,180 |
| Oxford University Hospitals Nhs Ft | £1,023,321 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £505,446 |
| University Hospital Southampton Nhs Ft | £414,300 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.